急性脑梗死行尤瑞克林联合依达拉奉治疗的疗效及对CRP的动态影响(1)
摘要：目的 分析急性脑梗死行尤瑞克林联合依达拉奉治疗的效果及对CRP动态影响。方法 回顾性分析2009年11月～2014年11月本院收治的60例急性脑梗死患者临床资料，按不同治疗方案分两组，每组各30例。行常规治疗者设对照组，于对照组基础上加用尤瑞克林、依达拉奉治疗者设研究组，对比两组疗效及CRP变化。结果 研究组治疗总有效率高于对照组，差异有统计学意义(P<0.05)；两组治疗前CRP水平均无明显差异(P>0.05)，治疗后CRP水平呈现下降，研究组下降幅度大于对照组，差异具统计学意义(P<0.05)。结论 急性脑梗死行尤瑞克林联合依达拉奉治疗可改善患者神经功能，并在降低CRP水平基础上促进患者预后改善。
关键词：急性脑梗死；尤瑞克林；依达拉奉；疗效；CRP
Effect of Yurek Lin Combined with Edaravone in Treatment of Acute Cerebral Infarction and the Influence of CRP
, 百拇医药
MU Dao-qiang
(Changsha Rongcheng Hospital，Changsha 410119，Hunan，China)
Abstract：Objective The analysis of efficacy and dynamic influence for CRP that urinary kallidinogenase combined with edaravone on acute cerebral infarction.Methods The clinical data of 60 cases with acute cerebral infarction from November 2009 to November 2014 in this hospital were analysed retrospectively， according to different therapeutic schedule，it divided into two groups，30 cases for each group.The cases with conventional treatments acted as comparison group，The cases with treatments of urinary kallidinogenase combined with edaravone based on comparison group acted as a group for research，Compared the efficacy and change of CRP for these two groups.Results The researchful group have higher efficiency than the comparison group，the difference have statistical significance(P<0.05)；it was no obvious difference between these two groups before the treatment have accepted(P>0.05)， the level of CRP took on a descenting situation .the declining range for researchful group was greater than the comparison group，the difference have statistical significance(P<0.05). Conclusion The treatment of urinary kallidinogenase combined with edaravone on acute cerebral infarction can improve patients 'neurological function and promote their improvement after cure based on declining the CRP level
, 百拇医药
Key words：Acute cerebral infarction；Urinary kallidinogenase；Edaravone；Therapeutic effect；CRP
急性脑梗死发病率与病死率均较高，临床治疗关键在于改善或恢复缺血脑组织灌注以避免再损伤[1]。本次通过回顾性分析60例患者临床资料，以分析急性脑梗死行尤瑞克林联合依达拉奉治疗的疗效及对CRP(超敏C反应蛋白)的动态影响，报告如下。
1资料与方法
1.1一般资料 回顾性分析2009年11月～2014年11月本院收治的60例急性脑梗死患者临床资料，患者均符合第四届脑血管病学术会议制定的脑梗死诊断标准[2]。按不同治疗方案分两组各30例；对照组男女比例17：13，年龄46～75岁，平均(65.18±9.70)岁；研究组男女比例15：15，年龄45～78岁，平均(65.80±9.51)岁；两组基本资料无明显差异(P>0.05)。
1.2方法 两组均予以镇静、吸氧、抗感染等常规治疗，予以阿司匹林(Bayer HealthCare Manufacturing S.r.l.，J20130078，0.1g/片)口服以抗血小板凝聚。研究组加用尤瑞克林(广东天普生化医药股份有限公司，H20052065，0.15单位)与依达拉奉(南京先声东元制药有限公司，H20050280，20ml：30mg)，0.15PNA单位尤瑞克林注入100ml生理盐水滴注，1次/d，300mg依达拉奉注入100ml生理盐水滴注，2次/d，两组疗程均为2w。CRP检测：患者治疗前、治疗1w及2w后于空腹清晨采3ml血行血清分离，以免疫比浊法测定CRP水平。, 百拇医药(牟道强)
关键词：急性脑梗死；尤瑞克林；依达拉奉；疗效；CRP
Effect of Yurek Lin Combined with Edaravone in Treatment of Acute Cerebral Infarction and the Influence of CRP
, 百拇医药
MU Dao-qiang
(Changsha Rongcheng Hospital，Changsha 410119，Hunan，China)
Abstract：Objective The analysis of efficacy and dynamic influence for CRP that urinary kallidinogenase combined with edaravone on acute cerebral infarction.Methods The clinical data of 60 cases with acute cerebral infarction from November 2009 to November 2014 in this hospital were analysed retrospectively， according to different therapeutic schedule，it divided into two groups，30 cases for each group.The cases with conventional treatments acted as comparison group，The cases with treatments of urinary kallidinogenase combined with edaravone based on comparison group acted as a group for research，Compared the efficacy and change of CRP for these two groups.Results The researchful group have higher efficiency than the comparison group，the difference have statistical significance(P<0.05)；it was no obvious difference between these two groups before the treatment have accepted(P>0.05)， the level of CRP took on a descenting situation .the declining range for researchful group was greater than the comparison group，the difference have statistical significance(P<0.05). Conclusion The treatment of urinary kallidinogenase combined with edaravone on acute cerebral infarction can improve patients 'neurological function and promote their improvement after cure based on declining the CRP level
, 百拇医药
Key words：Acute cerebral infarction；Urinary kallidinogenase；Edaravone；Therapeutic effect；CRP
急性脑梗死发病率与病死率均较高，临床治疗关键在于改善或恢复缺血脑组织灌注以避免再损伤[1]。本次通过回顾性分析60例患者临床资料，以分析急性脑梗死行尤瑞克林联合依达拉奉治疗的疗效及对CRP(超敏C反应蛋白)的动态影响，报告如下。
1资料与方法
1.1一般资料 回顾性分析2009年11月～2014年11月本院收治的60例急性脑梗死患者临床资料，患者均符合第四届脑血管病学术会议制定的脑梗死诊断标准[2]。按不同治疗方案分两组各30例；对照组男女比例17：13，年龄46～75岁，平均(65.18±9.70)岁；研究组男女比例15：15，年龄45～78岁，平均(65.80±9.51)岁；两组基本资料无明显差异(P>0.05)。
1.2方法 两组均予以镇静、吸氧、抗感染等常规治疗，予以阿司匹林(Bayer HealthCare Manufacturing S.r.l.，J20130078，0.1g/片)口服以抗血小板凝聚。研究组加用尤瑞克林(广东天普生化医药股份有限公司，H20052065，0.15单位)与依达拉奉(南京先声东元制药有限公司，H20050280，20ml：30mg)，0.15PNA单位尤瑞克林注入100ml生理盐水滴注，1次/d，300mg依达拉奉注入100ml生理盐水滴注，2次/d，两组疗程均为2w。CRP检测：患者治疗前、治疗1w及2w后于空腹清晨采3ml血行血清分离，以免疫比浊法测定CRP水平。, 百拇医药(牟道强)